This database contains 40 studies, archived under the term: "AD patients"
Click here to filter this large number of results.
Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease – protocol for a controlled, randomized double-blinded trial
Egefjord, Lærke,
Gejl, Michael,
Møller, Arne,
Brændgaard, Hans,
Gottrup, Hanne,
Antropova, Olga,
Møller, Niels,
Poulsen, Henrik E.,
Gjedde, Albert,
Brock, Birgitte,
Rungby, Jørgen
Introduction: Type 2 diabetes (DM-2) increases the risk of developing Alzheimer´s disease (AD), and patients with AD are more likely to develop DM-2. DM-2 and AD share some pathophysiological features. In AD, amyloid-β (Aβ) is accumulated as extracellular plaques in the gray matter of the brain, while in DM-2 islet amyloid polypeptide (IAPP) is accumulated […]
Effect of second-generation antipsychotics on caregiver burden in Alzheimer’s disease
Mohamed, Somaia,
Rosenheck, Robert,
Lyketsos, Constantine G.,
Kaczynski, Richard,
Sultzer, David L.,
Schneider, Lon S.
Background: Alzheimer’s disease (AD) imposes a severe burden upon patients and their caregivers. Severity of psychiatric symptoms and behavioral disturbances is an important determinant of caregivers’ experience of burden. These symptoms may be improved with atypical antipsychotic treatment.; Objective: Data from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) trial were used to evaluate […]
Longitudinal changes of fractional anisotropy in Alzheimer’s disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study
Likitjaroen, Y.,
Meindl, T.,
Friese, U.,
Wagner, M.,
Buerger, K.,
Hampel, H.,
Teipel, S. J.
Diffusion tensor imaging (DTI) demonstrates decline of fractional anisotropy (FA) as a marker of fiber tract integrity in Alzheimer’s disease (AD). We aimed to assess the longitudinal course of white matter microstructural changes in AD and healthy elderly control (HC) subjects and to evaluate the effects of treatment with the cholinesterase inhibitor galantamine on white […]
Medication adherence and tolerability of Alzheimer’s disease medications: study protocol for a randomized controlled trial
Campbell, Noll L.,
Dexter, Paul,
Perkins, Anthony J.,
Gao, Sujuan,
Li, Lang,
Skaar, Todd C.,
Frame, Amie,
Hendrie, Hugh C.,
Callahan, Chris M.,
Boustani, Malaz A.
Background: The class of acetylcholinesterase inhibitors (ChEI), including donepezil, rivastigmine, and galantamine, have similar efficacy profiles in patients with mild to moderate Alzheimer’s disease (AD). However, few studies have evaluated adherence to these agents. We sought to prospectively capture the rates and reasons for nonadherence to ChEI and determine factors influencing tolerability and adherence.; Methods/design: […]
Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD
Egan, Michael,
Yaari, Roy,
Liu, Lian,
Ryan, Michael,
Peng, Yahong,
Lines, Christopher,
Michelson, David
We performed a clinical trial to evaluate the effects of the histamine subtype-3 receptor inverse agonist MK- 0249 on cognition in AD patients. Mild-to-moderate AD patients were randomized 1:1 to 4 weeks of double-blind daily treatment with oral MK-0249 5-mg or placebo. Pharmacokinetic and PET data suggested that MK-0249 5-mg daily would achieve approximately 85% […]
Effect of acupuncture in mild cognitive impairment and Alzheimer disease: a functional MRI study
Wang, Z.,
Nie, B.,
Li, D.,
Zhao, Z.,
Han, Y.,
Song, H.,
Xu, J.,
Shan, B.,
Lu, J.,
Li, K.
We aim to clarify the mechanisms of acupuncture in treating mild cognitive impairment (MCI) and Alzheimer disease (AD) by using functional magnetic resonance imaging (fMRI). Thirty-six right-handed subjects (8 MCI patients, 14 AD patients, and 14 healthy elders) participated in this study. Clinical and neuropsychological examinations were performed on all the subjects. MRI data acquisition […]
Healing gardens and cognitive behavioral units in the management of Alzheimer’s disease patients: the Nancy experience
Rivasseau Jonveaux, T.,
Batt, M.,
Fescharek, R.,
Benetos, A.,
Trognon, A.,
Bah Chuzeville, S.,
Pop, A.,
Jacob, C.,
Yzoard, M.,
Demarche, L.,
Soulon, L.,
Malerba, G.,
Bouvel, B.
The French Alzheimer Plan 2008-2012 anticipates the implementation of new Units specialized in cognitive rehabilitation and psycho-behavioral therapy of Alzheimer’s disease (AD) patients. Conceived for AD and other dementia patients of all ages, their objectives are to propose a cognitive rehabilitation program, to prevent or treat psycho-behavioral crises, and to provide support and educational therapy […]
Validation of AclarusDx™, a blood-based transcriptomic signature for the diagnosis of Alzheimer’s disease
Fehlbaum-Beurdeley, Pascale,
Sol, Olivier,
Désiré, Laurent,
Touchon, Jacques,
Dantoine, Thierry,
Vercelletto, Martine,
Gabelle, Audrey,
Jarrige, Anne-Charlotte,
Haddad, Raphaël,
Lemarié, Jean Christophe,
Zhou, Weiyin,
Hampel, Harald,
Einstein, Richard,
Vellas, Bruno
Biomarkers have gained an increased importance in the past years in helping physicians to diagnose Alzheimer’s disease (AD). This study was designed to identify a blood-based, transcriptomic signature that can differentiate AD patients from control subjects. The performance of the signature was then evaluated for robustness in an independent blinded sample population. RNA was extracted […]
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, Norman R.,
Szabo, Paul,
Adamiak, Basia,
Burgut, Tuna,
Monthe, Carmen,
Lent, Richard W.,
Younkin, Steven,
Younkin, Linda,
Schiff, Richard,
Weksler, Marc E.
Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer’s disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Abeta). We carried out an open label dose-ranging study in 8 mild AD patients in which IVIg was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. […]